Intravenous Mistletoe Therapy

Intravenous Mistletoe Therapy unique treatment, rooted in centuries-old traditions, has been gaining recognition in the modern medical world for its potential health benefits. Whether you're seeking to boost your immune system, improve your overall wellbeing, or are interested in exploring alternative therapies, this guide will provide you with a detailed understanding of what Intravenous Mistletoe Therapy entails.

What is Intravenous Mistletoe Therapy?

Intravenous Mistletoe Therapy is a form of treatment that involves the administration of mistletoe extract directly into the bloodstream. The mistletoe plant, scientifically known as Viscum album, has been used for centuries in traditional medicine due to its healing properties.

In this therapy, the mistletoe extract, which is rich in a variety of bioactive compounds, is prepared in a sterile environment and then administered intravenously. This allows the beneficial compounds to be rapidly absorbed and distributed throughout the body, providing a direct and potent therapeutic effect.

The therapy is based on the principle that the mistletoe extract can stimulate the immune system, enhance the body's natural healing processes, and improve overall health and wellbeing. It's often used as a complementary therapy in conjunction with other treatments, particularly in the field of integrative medicine.

Benefits of Intravenous Mistletoe Therapy

Intravenous Mistletoe Therapy is a unique treatment approach that has been gaining recognition for its numerous health benefits. Here are some of the key advantages of this therapy:

• Boosts Immune System: Mistletoe extracts are known to stimulate the immune system, enhancing your body's natural defense against diseases. This can be particularly beneficial for individuals with weakened immune systems or those undergoing treatments that may suppress immune function, such as chemotherapy.

• Improves Quality of Life: Many patients report an improved sense of wellbeing and quality of life after undergoing Intravenous Mistletoe Therapy. This can include increased energy levels, improved appetite, and a reduction in treatment-related side effects.

• Potential Anti-Cancer Properties: Some studies suggest that mistletoe extracts can slow the growth of cancer cells and stimulate apoptosis, or programmed cell death. While more research is needed, these findings are promising for the potential use of mistletoe therapy as a complementary cancer treatment.

• Pain Management: Mistletoe therapy may help manage pain, particularly in patients dealing with chronic conditions. Its analgesic properties can provide relief and improve overall comfort.

Who Can Benefit from Intravenous Mistletoe Therapy?

Intravenous Mistletoe Therapy can be beneficial for a wide range of individuals. It is often recommended for patients who are undergoing conventional cancer treatments, as it can help manage side effects and improve overall wellbeing.

People with chronic conditions that impact the immune system may also find value in this therapy. By boosting the immune response, mistletoe therapy can enhance the body's ability to fight off infections and disease.

Furthermore, individuals seeking to improve their general health and wellness may also consider Intravenous Mistletoe Therapy. Its potential to boost energy levels, improve mood, and enhance overall quality of life makes it a compelling option for those seeking holistic approaches to health.

Please note that while Intravenous Mistletoe Therapy can offer numerous benefits, it's important to discuss with a healthcare professional to determine if this treatment is right for you. Individual health circumstances can greatly impact the effectiveness and suitability of this therapy.

The Procedure of Intravenous Mistletoe Therapy

Intravenous Mistletoe Therapy is a relatively straightforward procedure that is typically administered in a clinical setting. Here's what you can expect:

• Consultation: Before starting the therapy, you'll have a consultation with a healthcare professional. They will review your medical history, discuss your health goals, and determine if this therapy is suitable for you.

• Preparation: On the day of the treatment, a nurse or medical practitioner will prepare the mistletoe extract. The extract is typically diluted in a saline solution to create the IV infusion.

• Administration: The mistletoe infusion is administered intravenously, usually via a vein in your arm. The infusion process typically takes between 30 minutes to an hour, during which you can relax in a comfortable chair.

• Post-Procedure: After the infusion, you may be monitored for a short period to ensure there are no immediate adverse reactions. You should be able to resume your normal activities after the treatment.

The frequency and duration of the therapy can vary depending on your individual health needs and the recommendations of your healthcare provider.

Potential Side Effects

While Intravenous Mistletoe Therapy is generally well-tolerated, like any treatment, it can have potential side effects. These may include:

• Local Reactions: Some people may experience redness, swelling, or discomfort at the injection site. These reactions are usually mild and resolve on their own.

• Flu-like Symptoms: Some patients may experience flu-like symptoms, including fever, chills, headache, and fatigue. These symptoms are typically temporary and can be managed with over-the-counter medications.

• Allergic Reactions: Though rare, allergic reactions to mistletoe extract can occur. Symptoms can include rash, itching, shortness of breath, and in severe cases, anaphylaxis. If you experience any signs of an allergic reaction, seek medical attention immediately.

It's important to discuss these potential side effects with your healthcare provider before starting the therapy. They can provide guidance on how to manage these side effects and monitor your response to the treatment. Always report any new or worsening symptoms to your healthcare provider promptly.

FAQs about Intravenous Mistletoe Therapy

• What does Intravenous Mistletoe Therapy involve? Intravenous Mistletoe Therapy involves the administration of mistletoe extract directly into the bloodstream. The exact dosage and frequency of treatments will depend on your individual health circumstances and will be determined by your healthcare provider.

• Are there any side effects? While generally well-tolerated, some individuals may experience mild side effects such as fever, chills, or allergic reactions. It's important to discuss potential side effects with your healthcare provider before starting treatment.

• How soon can I expect to see results? The timeline for seeing results can vary greatly depending on individual health circumstances. Some patients report feeling better after a few sessions, while others may require longer treatment periods. Your healthcare provider can give you a better idea of what to expect.

• Is Intravenous Mistletoe Therapy covered by insurance? Coverage for Intravenous Mistletoe Therapy can vary by insurance provider and plan. It's recommended to check with your insurance company to understand your coverage options.

Ready to explore the benefits of Intravenous Mistletoe Therapy? At our clinic, we're committed to providing personalized, holistic care that prioritizes your health and wellness. Our experienced team is here to guide you through every step of the process, from initial consultation to post-treatment care.

Whether you're seeking to boost your immune system, manage chronic pain, or enhance your overall wellbeing, Intravenous Mistletoe Therapy could be a valuable addition to your healthcare regimen.

Don't wait to take the next step in your health journey. Contact us today to schedule a consultation and learn more about how Intravenous Mistletoe Therapy can improve your quality of life. Let's work together to create a treatment plan that's tailored to your unique needs and health goals.

Contact Us Today

References 

1. Kienle G., Kiene H. (2003) Verträglichkeit, Nebenwirkungen, Überempfindlichkeitsreaktionen, Toxizität. In: Kienle G., Kiene H., Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Stuttgart: Schattauer 2003, 591–607.
2. Büssing A: Biological and pharmacological properties of Viscum album L. In Büssing A (Ed): Mistletoe – The Genus Viscum. Harwood Academic Publishers, Amsterdam, 124-182 (2000).
3. Kienle GS, Kiene H, Albonico HU: Anthroposophic Medicine: Effectiveness, Utility, Costs, Safety. Stuttgart, New York: Schattauer Verlag; 2006.
4. Struh CM, Jager S, Schempp CM, et al. A novel triterpene extract from mistletoe induces rapid apoptosis in murine B16.F10 melanoma cells. Phytother Res. Oct 2012;26(10):1507-1512. doi: 10.1002/ptr.4604
5. Beuth J, Ko HL, Schneider H, et al. Intratumoral application of standardized mistletoe extracts down regulates tumor weight via decreased cell proliferation, increased apoptosis and necrosis in a murine model. Anticancer Res. Nov-Dec 2006;26(6B):4451-4456.
6. Shen JJ, Chiang MS, Kuo ML, et al. Partially purified extract and viscolin from Viscum coloratum attenuate airway inflammation and eosinophil infiltration in ovalbumin-sensitized mice. J Ethnopharmacol. Jun 1 2011;135(3): 646-653. doi: 10.1016/j.jep.2011.03.065
7. Troger W, Galun D, Reif M, et al. Viscum album [L.] extract therapy in patients with locally advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. Dec 2013;49(18):3788-3797. doi: 10.1016/j.ejca.2013.06.043
8. Troger W, Galun D, Reif M, et al. Quality of life of patients with advanced pancreatic cancer during treatment with mistletoe: a randomized controlled trial. Dtsch Arztebl Int. Jul 21 2014;111(29-30):493-502, 433 p following 502.
9. Bar-Sela G, Wollner M, Hammer L, et al. Mistletoe as complementary treatment in patients with advanced non- small- cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer. Mar 2013;49(5):1058-1064. doi: 10.1016/j.ejca.2012.11.007
10. Friedel WE, Matthes H, Bock PR, et al. Systematic evaluation of the clinical effects of supportive mistletoe treatment within chemo- and/or radiotherapy protocols and long-term mistletoe application in nonmetastatic colorectal carcinoma: multicenter, controlled, observational cohort study. J Soc Integr Oncol. Fall 2009;7(4): 137-145.
11. Troger W, Zdrale Z, Stankovic N, et al. Five-year follow-up of patients with early stage breast cancer after a randomized study comparing additional treatment with Viscum album (L.) extract to chemotherapy alone. Breast Cancer (Auckl). 2012;6:173-180. doi: 10.4137/bcbcr.s10558
12. Ostermann T, Raak C, Bussing A. Survival of cancer patients treated with mistletoe extract (Iscador): a systematic literature review. BMC Cancer. 2009;9:451. doi: 10.1186/1471-2407-9-451
13. Grossarth-Maticek R, Kiene H, Baumgartner SM, et al. Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. May-Jun 2001;7(3):57-66, 68-72, 74-56 passim.
14. Grossarth-Maticek R, Ziegler R. Randomised and non-randomised prospective controlled cohort studies in matched- pair design for the long-term therapy of breast cancer patients with a mistletoe preparation (Iscador): a re-analysis. Eur J Med Res. Nov 30 2006;11(11):485-495.
15. Bar-Sela G, Haim N. Abnoba-viscum (mistletoe extract) in metastatic colorectal carcinoma resistant to 5- fluorouracil and leucovorin-based chemotherapy. Med Oncol. 2004;21(3):251-254. doi: 10.1385/MO:21:3:251
16. Kleeberg UR, Suciu S, Brocker EB, et al. Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metastasis. Eur J Cancer. Feb 2004;40(3): 390-402.
17. Steuer-Vogt MK, Bonkowsky V, Ambrosch P, et al. The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur J Cancer. Jan 2001;37(1):23-31.
18. Rose A, El-Leithy T, vom Dorp F, et al. Mistletoe Plant Extract in Patients with Nonmuscle Invasive Bladder Cancer: Results of a Phase Ib/IIa Single Group Dose Escalation Study. J Urol. Oct 2015;194(4):939-943.
19. Cho JS, Na KJ, Lee Y, et al. Chemical Pleurodesis Using Mistletoe Extraction (ABNOVAviscum((R)) Injection) for Ann Thorac Cardiovasc Surg. 2016;22(1):20-26.
20. Beuth J, Schneider B, Schierholz JM. Impact of complementary treatment of breast cancer patients with standardized mistletoe extract during aftercare: a controlled multicenter comparative epidemiological cohort study. Anticancer Res. Jan-Feb 2008;28(1b):523-527.
21. Mansky PJ, Wallerstedt DB, Sannes TS, et al. NCCAM/NCI Phase 1 Study of Mistletoe Extract and Gemcitabine in Patients with Advanced Solid Tumors. Evid Based Complement Alternat Med. 2013;2013:964592. doi: 10.1155/2013/964592
22. Franz H, Ziska P, Kindt A: Isolation and properties of three lectins from mistletoe ( Viscum album L.). Biochemical Journal 1981, 195:481-484.
23. Winterfeld K, Bijnen AB: Viscotoxin, ein neuer Inhaltsstoff der Mistel ( Viscum album L.). Liebigs Ann Chem 1948, 561:107- 115.
24. Urech K, Scher JM, Hostanska K, Becker H: Apoptosis inducing activity of viscin, a lipophilic extract from Viscum album L. Journal of Pharmacy and Pharmacology 2005, 57 101-109.
25. Winterfeld K, Kronenthaler A: Zur Chemie des blutdrucksenkenden Bestandteils der Mistel. (Viscum album). Arch Pharm 1942, 280:103-115.
26. Mueller EA, Anderer FA: A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol Immunother 1990, 32:221-227.
27. Klett CY, Anderer FA: Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from Viscum album extract. Arzneimittel-Forschung/Drug Research 1989, 39 (II)(12):1580-1585.
28. Struh CM, Jager S, Kersten A, Schempp CM, Scheffler A, Martin SF: Triterpenoids amplify antitumoural effects of mistletoe extracts on murine B16.f10 melanoma in vivo. PLoS One 2013, 8(4):e62168.
29. Delebinski CI, Jaeger S, Kemnitz-Hassanin K, Henze G, Lode HN, Seifert GJ: A new development of triterpene acid- containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia. Cell Prolif 2012, 45(2):176-187.
30. Kleinsimon S, Kauczor G, Jaeger S, Eggert A, Seifert G, Delebinski C: ViscumTT induces apoptosis and alters IAP expression in osteosarcoma in vitro and has synergistic action when combined with different chemotherapeutic drugs. BMC Complement Altern Med 2017, 17(1):26.
31. Twardziok M, Kleinsimon S, Rolff J, Jager S, Eggert A, Seifert G, Delebinski CI: Multiple Active Compounds from Viscum album L. Synergistically Converge to Promote Apoptosis in Ewing Sarcoma. PLoS One 2016, 11(9):e0159749.
32. Saller R., Kramer S., Iten F., Melzer J. (2005) Unerwünschte Wirkungen der Misteltherapie bei Tumourpatien- ten – Eine systematische Übersicht. In: Scheer R., Bauer R., Becker H., Fintelmann V., Kemper F. H., Schil- cher H. (Hrsg.), Fortschritte in der Misteltherapie: Aktueller Stand der Forschung und klinische Anwendung. Essen: KVC Verlag 2005, 367–403.
33. Urech et al.: Triterpenes of mistletoe (VIscum album) in the “bird-lime” Viscin and its antiprolifertive activity. In Scheer R et al (Ed): Fortschritte in Der Misteltherapie. KVC Verlag, Essen, 133-144 (2005)
34. Melzer J, Iten F, Hostanska K, et al. Efficacy and safety of mistletoe preparations (Viscum album) for patients with cancer diseases. A systematic review. Forsch Komplementmed. Aug 2009;16(4):217-226. doi: 10.1159/000226249
35. Goebell PJ, Otto T, Suhr J, et al. Evaluation of an unconventional treatment modality with mistletoe lectin to prevent recurrence of superficial bladder cancer: a randomized phase II trial. J Urol. Jul 2002;168(1):72-75.
36. Elluru SR, Duong van Huyen JP, Delignat S, et al. Induction of maturation and activation of human dendritic cells: a mechanism underlying the beneficial effect of Viscum album as complimentary therapy in cancer. BMC Cancer. 2008;8:161. doi: 10.1186/1471-2407-8-161
37. Delebinski CI, Jaeger S, Kemnitz-Hassanin K, et al. A new development of triterpene acid-containing extracts from Viscum album L. displays synergistic induction of apoptosis in acute lymphoblastic leukaemia. Cell Prolif. Apr 2012;45(2):176-187. doi: 10.1111/j.1365-2184.2011.00801.
38. Struh CM, Jager S, Kersten A, et al. Triterpenoids amplify anti-tumoral effects of mistletoe extracts on murine B16.f10 melanoma in vivo. PLoS One. 2013;8(4):e62168. doi: 10.1371/journal.pone.0062168
39. Kleijnen J, Knipschild P. Mistletoe treatment for cancer review of controlled trials in humans. Phytomedicine. Dec 1994;1(3):255-260. doi: 10.1016/S0944-7113(11)80073-5
40. Lyu SY, Park WB. Effects of Korean mistletoe lectin (Viscum album coloratum) on proliferation and cytokine expression in human peripheral blood mononuclear cells and T-lymphocytes. Arch Pharm Res. Oct 2007;30(10): 1252-1264.
41. Weissenstein U, Kunz M, Urech K, et al. Interaction of standardized mistletoe (Viscum album) extracts with chemotherapeutic drugs regarding cytostatic and cytotoxic effects in vitro. BMC Complement Altern Med.2014;14:6. doi: 10.1186/1472-6882-14-6
42. Engdal S, Nilsen OG. In vitro inhibition of CYP3A4 by herbal remedies frequently used by cancer patients.Phytother Res. Jul 2009;23(7):906-912. doi: 10.1002/ptr.2750
43. Huber R, Eisenbraun J, Miletzki B, et al. Pharmacokinetics of natural mistletoe lectins after subcutaneous injection.Eur J Clin Pharmacol. Sep 2010;66(9):889-897. doi: 10.1007/s00228-010-0830-5
44. Schad F, Atxner J, Buchwald D, et al. Intratumoral Mistletoe (Viscum album L) Therapy in Patients WithUnresectable Pancreas Carcinoma: A Retrospective Analysis. Integr Cancer Ther. Jul 2014;13(4):332-340.
45. Steele ML, Axtner J, Happe A, et al. Use and safety of intratumoral application of European mistletoe (Viscumalbum L) preparations in Oncology. Integr Cancer Ther. Mar 2015;14(2):140-148.
46. Bussing A, Stumpf C, Troger W, et al. Course of mitogen-stimulated T lymphocytes in cancer patients treated withViscum album extracts. Anticancer Res. Jul-Aug 2007;27(4C):2903-2910.
47. Steele ML, Axtner J, Happe A, et al. Adverse Drug Reactions and Expected Effects to Therapy with SubcutaneousMistletoe Extracts (Viscum album L.) in Cancer Patients. Evid Based Complement Alternat
Med.2014;2014:724258. doi: 10.1155/2014/724258 Related articles:
48. Huber R, Ludtke R, Klassen M, et al. Effects of a mistletoe preparation with defined lectin content on chronichepatitis C: an individually controlled cohort study. Eur J Med Res. Sep 28 2001;6(9):399-405.
49. Horneber MA, Bueschel G, Huber R, et al. Mistletoe therapy in oncology. Cochrane Database Syst Rev.2008(2):CD003297. doi: 10.1002/14651858.CD003297.pub2
50. Bar-Sela G. White-berry mistletoe (Viscum album L.) as complementary treatment in cancer: Does it help? Eur JIntegr Med. 2011;3:e55-e62.
51. de Giorgio A, Stebbing J. Mistletoe: for cancer or just for Christmas? Lancet Oncol. Dec 2013;14(13):1264-1265.doi: 10.1016/s1470-2045(13)70560-6
52. Ernst E. Herbal medicinal products during pregnancy: are they safe? BJOG. Mar 2002;109(3):227-235.
53. Evens ZN, Stellpflug SJ. Holiday plants with toxic misconceptions. West J Emerg Med. Dec 2012;13(6):538-542.doi: 10.5811/westjem.2012.8.12572
54. Rosell S, Samuelsson G. Effect of mistletoe viscotoxin and phoratoxin on blood circulation. Toxicon. Aug1966;4(2):107-110.
55. Finall AI, McIntosh SA, Thompson WD. Subcutaneous inflammation mimicking metastatic malignancy induced by injection of mistletoe extract. BMJ. Dec 23 2006;333(7582):1293-1294. doi: 10.1136/bmj.39044.460023.BE 56. Hall AH, Spoerke DG, Rumack BH. Assessing mistletoe toxicity. Ann Emerg Med. Nov 1986;15(11):1320 1323.
57. Kim HJ, Kim H, Ahn JH, et al. Liver injury induced by herbal extracts containing mistletoe and kudzu. J Altern Complement Med. Mar 2015;21(3):180-185.